
Bristol-Myers Squibb Company
BMYHealthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16
Next Earnings Report
Feb 4, 2027
EPS est. $1.56 · Revenue est. $12.66B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (27)
Nov 2026
Est. completion
P3Alzheimer Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787n=406
Nov 2026
Est. completion
P4Healthy Volunteers
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
NCT07681076n=180
Dec 2026
Est. completion
P2Non Small Cell Lung Cancer
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
NCT03527108n=36
Dec 2026
Est. completion
P1Healthy Volunteers
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
NCT07204418n=56
Dec 2026
Est. completion
P3Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224n=500
Mar 2027
Est. completion
P1Chronic Lymphocytic Leukemia (CLL)
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
NCT03085173n=39
Jul 2027
Est. completion
P1Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201n=120
Aug 2027
Est. completion
P1Solid Tumors
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
NCT02498912n=18
Sep 2027
Est. completion
Sep 2027
Est. completion
P3Psychosis Associated With Alzheimer's Disease
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949n=1,000
Dec 2027
Est. completion
P3Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479n=440
Dec 2027
Est. completion
P2Lymphoma, Non-Hodgkin
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535n=4,200
Jan 2028
Est. completion
P2Lymphoma
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242n=65
May 2028
Est. completion
P2Lupus Erythematosus, Systemic
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983n=89
Aug 2028
Est. completion
P1Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843n=187
Aug 2028
Est. completion
P1Systemic Lupus Erythematosus
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955n=270
Mar 2029
Est. completion
Mar 2029
Est. completion
P1Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745n=125
Mar 2030
Est. completion
P3Schizophrenia
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404n=400
May 2030
Est. completion
P1Relapsed and/or Refractory Multiple Myeloma
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251n=187
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Recent Press Releases
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
Nov 6, 2026 · Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
Oct 29, 2026 · Business Wire
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
Oct 26, 2026 · Business Wire
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie
Oct 25, 2026 · Globe News Wire
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Oct 23, 2026 · Business Wire
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Oct 23, 2026 · Business Wire
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
Oct 23, 2026 · Business Wire
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Oct 23, 2026 · Business Wire
SEC Filings (69)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 29, 2026 | 8-K | Material event | DocumentIndex |
| Aug 7, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jul 30, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 30, 2026 | 8-K | Material event | DocumentIndex |
| Jun 5, 2026 | 11-K | DocumentIndex | |
| Jun 5, 2026 | 11-K | DocumentIndex | |
| Jun 5, 2026 | 11-K | DocumentIndex | |
| May 8, 2026 | S-8 | Employee stock plan | DocumentIndex |
| May 8, 2026 | 8-K | Material event | DocumentIndex |
| Apr 30, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 30, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 17, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Mar 27, 2026 | 15-12G | DocumentIndex | |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 25, 2026 | ARS | Annual report to holders | DocumentIndex |
| Mar 25, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Mar 25, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Feb 11, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 5, 2026 | 8-K | Material event | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Nov 18, 2025 | 8-K | Material event | DocumentIndex |
| Nov 12, 2025 | CERT | DocumentIndex | |
| Nov 10, 2025 | 8-A12B | DocumentIndex | |
| Nov 10, 2025 | 8-K | Material event | DocumentIndex |
| Nov 7, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Nov 5, 2025 | FWP | DocumentIndex | |
| Nov 3, 2025 | 8-K | Material event | DocumentIndex |
| Nov 3, 2025 | 424B2 | Offering prospectus | DocumentIndex |
| Oct 31, 2025 | POSASR | DocumentIndex | |
| Oct 31, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 30, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 30, 2025 | 8-K | Material event | DocumentIndex |
| Jul 31, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Jul 31, 2025 | 8-K | Material event | DocumentIndex |
| Jul 25, 2025 | 8-K | Material event | DocumentIndex |
| Jun 6, 2025 | 11-K | DocumentIndex | |
| Jun 6, 2025 | 11-K | DocumentIndex | |
| Jun 6, 2025 | 11-K | DocumentIndex |